Vabysmo (faricimab-svoa)

Safety Data Sheets:

Publications and Congresses Clinical Trials Additional Resources

Publications

Visit PubMed.gov to browse a listing of published scientific literature about Vabysmo^®.

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomized, double-masked, phase 3, non-inferiority trials
Heier JS et al. Lancet 2022 Feb;399(10326):729-740.

VIEW

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
Wykoff CC, Abreu F, Adamis AP, et al. Lancet 2022 Feb 19;399:741-755.

VIEW

A Genentech Medical Science Liaison in your area can assist with medical questions about Vabysmo^® and other Genentech products.

Connect with an MSL

Scientific Congresses

Genentech maintains a presence at in-person and virtual scientific congresses worldwide. Find Genentech-sponsored posters and presentations from recent congresses at Medically.gene.com.

November 2-5, 2022
Onsite